BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Bone cancer AND MYH11, ENSG00000133392, 4629
53 results:

  • 1. Lymphatic vessels in bone support regeneration after injury.
    Biswas L; Chen J; De Angelis J; Singh A; Owen-Woods C; Ding Z; Pujol JM; Kumar N; Zeng F; Ramasamy SK; Kusumbe AP
    Cell; 2023 Jan; 186(2):382-397.e24. PubMed ID: 36669473
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. The Gene Expression Landscape of Prostate cancer BM Reveals Close Interaction with the bone Microenvironment.
    Saraji A; Duan K; Watermann C; Hempel K; Roesch MC; Krupar R; Stegmann-Frehse J; Jonigk D; Kuehnel MP; Klapper W; Merseburger AS; Kirfel J; Perner S; Offermann A; Sailer V
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361816
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. AML with inv(16)/t(16;16) and high-risk cytogenetic abnormalities: atypical features and unfavorable outcome.
    Assaf N; Lefebvre C; Raggueneau V; Guignedoux G; Marceau-Renaut A; Chevalier S; Tondeur S; Bories D; Benramdane R; Rousselot P; Terré C
    Hematology; 2022 Dec; 27(1):636-641. PubMed ID: 35622005
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Jumping translocation involving chromosome 13q in a patient with Crohn's Disease and inv(16)(p13.1q22)/CBFB-myh11 acute myeloid leukemia.
    Clarke S; de Kraa R; Chuah H; Creeper K; Leahy MF; Wright M
    Cancer Genet; 2022 Aug; 266-267():7-14. PubMed ID: 35613501
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Prognostic value of measurable residual disease at allogeneic transplantation for adults with core binding factor acute myeloid leukemia in complete remission.
    Konuma T; Kondo T; Masuko M; Shimizu H; Shiratori S; Fukuda T; Kato J; Sawa M; Ozawa Y; Ota S; Uchida N; Kanda Y; Kako S; Fujisawa S; Fukushima K; Ichinohe T; Atsuta Y; Yanada M;
    Bone Marrow Transplant; 2021 Nov; 56(11):2779-2787. PubMed ID: 34272486
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Incidental identification of inv(16)(p13.1q22)/
    Quesada AE; Luthra R; Jabbour E; Patel KP; Khoury JD; Tang Z; Alvarez H; Mallampati S; Garcia-Manero G; Montalban-Bravo G; Medeiros LJ; Kanagal-Shamanna R
    Cold Spring Harb Mol Case Stud; 2021 Jun; 7(3):. PubMed ID: 34117074
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. The Identification of Key Gene Expression Signature in Prostate cancer.
    Huang Y; Cao Q; Song Z; Ruan H; Wang K; Chen K; Zhang X
    Crit Rev Eukaryot Gene Expr; 2020; 30(2):153-168. PubMed ID: 32558494
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Detection of del(16q) using the CBFB-myh11 translocation dual fusion probe.
    Temerik DF; El-Mahdy WT; Ahmed AM
    Hematol Oncol Stem Cell Ther; 2021 Dec; 14(4):351-352. PubMed ID: 32202250
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Measurable residual disease assessment by qPCR in peripheral blood is an informative tool for disease surveillance in childhood acute myeloid leukaemia.
    Juul-Dam KL; Ommen HB; Nyvold CG; Walter C; VĂ„lerhaugen H; Kairisto V; Abrahamsson J; Alm SJ; Jahnukainen K; Lausen B; Reinhardt D; Zeller B; von Neuhoff N; Fogelstrand L; Hasle H
    Br J Haematol; 2020 Jul; 190(2):198-208. PubMed ID: 32175599
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Myeloid Sarcoma With CBFB-myh11 Fusion (inv(16) or t(16;16)) Prevails in the Abdomen.
    Dalland JC; Meyer R; Ketterling RP; Reichard KK
    Am J Clin Pathol; 2020 Feb; 153(3):333-341. PubMed ID: 31671434
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Detection of a novel CBFB-myh11 fusion transcript in acute myeloid leukemia M1 with inv(16)(p13q22).
    Kurata K; Yamamoto K; Okazaki Y; Noguchi Y; Matsui K; Matsumoto H; Inui Y; Yakushijin K; Ito M; Nakamachi Y; Matsuoka H; Saegusa J; Minami H
    Cancer Genet; 2020 Feb; 241():72-76. PubMed ID: 31353165
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. ssExpression level of GAS6-mRNA influences the prognosis of acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation.
    Yang X; Shi J; Zhang X; Zhang G; Zhang J; Yang S; Wang J; Ke X; Fu L
    Biosci Rep; 2019 May; 39(5):. PubMed ID: 31028135
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. CSF3R Mutations are frequently associated with abnormalities of RUNX1, CBFB, CEBPA, and NPM1 genes in acute myeloid leukemia.
    Zhang Y; Wang F; Chen X; Zhang Y; Wang M; Liu H; Cao P; Ma X; Wang T; Zhang J; Zhang X; Lu P; Liu H
    Cancer; 2018 Aug; 124(16):3329-3338. PubMed ID: 29932212
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Clinical and biological implications of mutational spectrum in acute myeloid leukemia of FAB subtypes M4 and M5.
    Cheng Z; Hu K; Tian L; Dai Y; Pang Y; Cui W; Zhao H; Qin T; Han Y; Hu N; Chen L; Wang C; Zhang Y; Wu D; Ke X; Shi J; Fu L
    Cancer Gene Ther; 2018 May; 25(3-4):77-83. PubMed ID: 29491461
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Copy number alterations determined by single nucleotide polymorphism array testing in the clinical laboratory are indicative of gene fusions in pediatric cancer patients.
    Busse TM; Roth JJ; Wilmoth D; Wainwright L; Tooke L; Biegel JA
    Genes Chromosomes Cancer; 2017 Oct; 56(10):730-749. PubMed ID: 28597942
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Enhancing acute myeloid leukemia therapy - monitoring response using residual disease testing as a guide to therapeutic decision-making.
    Tomlinson B; Lazarus HM
    Expert Rev Hematol; 2017 Jun; 10(6):563-574. PubMed ID: 28475434
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Most Myeloid Neoplasms With Deletion of Chromosome 16q Are Distinct From Acute Myeloid Leukemia With Inv(16)(p13.1q22): A bone Marrow Pathology Group Multicenter Study.
    Rogers HJ; Hsi ED; Tang G; Wang SA; Bueso-Ramos CE; Lubin D; Morrissette JJ; Bagg A; Cherukuri DP; George TI; Peterson L; Liu YC; Mathew S; Orazi A; Hasserjian RP
    Am J Clin Pathol; 2017 Apr; 147(4):411-419. PubMed ID: 28375434
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm.
    Salem A; Loghavi S; Tang G; Huh YO; Jabbour EJ; Kantarjian H; Wang W; Hu S; Luthra R; Medeiros LJ; Khoury JD
    Am J Hematol; 2017 Jun; 92(6):520-528. PubMed ID: 28253536
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis.
    Struski S; Lagarde S; Bories P; Puiseux C; Prade N; Cuccuini W; Pages MP; Bidet A; Gervais C; Lafage-Pochitaloff M; Roche-Lestienne C; Barin C; Penther D; Nadal N; Radford-Weiss I; Collonge-Rame MA; Gaillard B; Mugneret F; Lefebvre C; Bart-Delabesse E; Petit A; Leverger G; Broccardo C; Luquet I; Pasquet M; Delabesse E
    Leukemia; 2017 Mar; 31(3):565-572. PubMed ID: 27694926
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia.
    Ouyang J; Goswami M; Peng J; Zuo Z; Daver N; Borthakur G; Tang G; Medeiros LJ; Jorgensen JL; Ravandi F; Wang SA
    Am J Clin Pathol; 2016 Jun; 145(6):769-77. PubMed ID: 27298396
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 3.